Literature DB >> 3079806

The suppressive effect of gangliosides upon IL 2-dependent proliferation as a function of inhibition of IL 2-receptor association.

R J Robb.   

Abstract

Gangliosides inhibited the proliferation of mitogen-activated human peripheral blood lymphocytes and the IL 2-dependent growth of murine T cell lines and 5-day-old human PHA lymphoblasts. In the case of the murine cell lines and PHA lymphoblasts, most of the effect of gangliosides could be reversed by the addition of high levels of IL 2. In the case of freshly-stimulated mitogen blasts, however, the ganglioside-induced inhibition could not be reversed by increasing exogenous IL 2 levels. These results indicate that inhibition of proliferation by gangliosides can be divided into IL 2-reversible and IL 2-irreversible mechanisms, the latter of which were predominant during the initial stage of cellular activation. Inclusion of gangliosides in receptor binding assays for radiolabeled IL 2 indicated that the IL 2-reversible mechanism likely involved competition between gangliosides and the cellular receptor for the binding of IL 2. Gangliosides blocked binding of radiolabeled IL 2 to both the high and low affinity forms of the IL 2 receptor, and this effect was most noticeable when the gangliosides and IL 2 were preincubated before addition of the target cells. In contrast, treatment of cells with gangliosides had no effect on the affinity of the cellular IL 2 receptor if the free gangliosides were removed immediately before the binding assay. Gangliosides also blocked the binding of radiolabeled IL 2 to anti-IL 2 antibodies, supporting the notion that their inhibitory effect is mediated via a direct interaction with IL 2. Thus, one major mechanism by which gangliosides block the IL 2-dependent proliferation of activated cells is by the sequestering or inactivation of the IL 2 molecule. This effect is reversible with the addition of excess IL 2, which distinguishes it from other mechanisms of ganglioside-dependent inhibition operating during the cellular activation process.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3079806

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

1.  A procedure for the preparation of GM3 ganglioside from GM1-lactone.

Authors:  L Mauri; R Casellato; G Kirschner; S Sonnino
Journal:  Glycoconj J       Date:  1999-03       Impact factor: 2.916

2.  Tumour infiltrating lymphocytes: insights into tumour immunology and potential therapeutic implications.

Authors:  K F Yoong; D H Adams
Journal:  Clin Mol Pathol       Date:  1996-10

3.  Ganglioside-exposed dendritic cells inhibit T-cell effector function by promoting regulatory cell activity.

Authors:  Alessandra Jales; Rustom Falahati; Elisabeth Mari; Erik J Stemmy; Weiping Shen; Cathy Southammakosane; Dallen Herzog; Stephan Ladisch; David Leitenberg
Journal:  Immunology       Date:  2010-09-28       Impact factor: 7.397

4.  Hypothalamic control of certain aspects of natural immunity in the mouse.

Authors:  N Belluardo; G Mudó; S Cella; A Santoni; G Forni; M Bindoni
Journal:  Immunology       Date:  1987-10       Impact factor: 7.397

5.  Gangliosides inhibit the development from monocytes to dendritic cells.

Authors:  M Wölfl; W Y Batten; C Posovszky; H Bernhard; F Berthold
Journal:  Clin Exp Immunol       Date:  2002-12       Impact factor: 4.330

6.  Fine specificity of natural killer T cells against GD3 ganglioside and identification of GM3 as an inhibitory natural killer T-cell ligand.

Authors:  Jun-Eui Park; Dianna Y Wu; Maria Prendes; Sharon X Lu; Govind Ragupathi; Nicolas Schrantz; Paul B Chapman
Journal:  Immunology       Date:  2008-01       Impact factor: 7.397

7.  Gangliosides as bimodal regulators of cell growth.

Authors:  S Spiegel; P H Fishman
Journal:  Proc Natl Acad Sci U S A       Date:  1987-01       Impact factor: 11.205

8.  Ceramide structure predicts tumor ganglioside immunosuppressive activity.

Authors:  S Ladisch; R Li; E Olson
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-01       Impact factor: 11.205

9.  Potentiation of interleukin-2 production and its binding by monoclonal antibodies to the gangliosides GD3 and GD2.

Authors:  S Schibeci; P Hersey; D Cheresh
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

10.  Gangliosides inhibit T-lymphocyte proliferation by preventing the interaction of interleukin-2 with its cell surface receptors.

Authors:  J W Chu; F J Sharom
Journal:  Immunology       Date:  1993-05       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.